Artimplant interim report january 1 - june 30, 2003

ARTIMPLANT INTERIM REPORT January 1 - June 30, 2003 - Consolidated net sales January-June 2003 reached SEK 14,7 million (SEK 13,1 million) - The loss after taxes was SEK 10,9 million (SEK 28,2 million loss). The reduced loss was a result of the company´s restructuring program. - Earnings per share for the period was SEK - 0,45 - Artimplant commenced shipment of ArtelonTM Augmentation Device ACL - 3-year results from the ArtelonTM Spacer CMC-I pilot study show that patients remain painless and stable - 1-year results confirm that accelerated rehabilitation with Artelon Augmentation Device ACL is possible Developments after the 6 month period - In July Artimplant filed for FDA approval of ArtelonTM Surgical Suture - In August Artimplant received CE-certificate for ArtelonTM Spacer CMC-I Forthcoming financial reports: January-September 2003 report: November 7, 2003 Release of year end results: February 17, 2004 Financial reports are available at www.artimplant.se at the same time that they're distributed to the media. For more information, contact: Tord Lendau, CEO, +46 (0)31 746 56 00, +46 708 369 403, tord.lendau@artimplant.se ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2003/08/29/20030829BIT00050/wkr0001.doc The full report http://www.waymaker.net/bitonline/2003/08/29/20030829BIT00050/wkr0002.pdf The full report